An interventional study of lower limb neuromuscular electrical stimulation and pulmonary rehabilitation exercises in Chronic Obstructive Pulmonary Disease (COPD), Neuromuscular Electrical Stimulation (NMES) and Exercise Self-Efficacy, sponsored by Kaohsiung Medical University Chung-Ho Memorial Hospital. Enrolling by invitation at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-20.
Sponsored by Kaohsiung Medical University Chung-Ho Memorial Hospital · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 158 studies in Pulmonary Disease, Chronic Obstructive with a site in Taiwan — 28 open to participants now, 30 under way, 6 of them phase 3. Pulmonary Disease, Chronic Obstructive · Taiwan.
Among the 158 studies in Pulmonary Disease, Chronic Obstructive with a site in Taiwan, this one is the 100th largest by planned enrollment of the 124 interventional ones that give a count, is one of 13 that started in 2025, is one of 51 with no phase, reaches primary completion later than 5 of the 29 other live ones, and was the 137th registered.
5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →28 of the 158 studies in Pulmonary Disease, Chronic Obstructive with a site in Taiwan are open now. Recruiting first, the newest first:
National Yang Ming Chiao Tung University Hospital · Sites in Taiwan
Ages 40–90
Fu Jen Catholic University Hospital · Sites in Taiwan
Ages 40+
Fu Jen Catholic University · Sites in Taiwan
Ages 18+ · Healthy volunteers
Pfizer · Sites in Taiwan, United States, Argentina and 15 more countries
Ages 35–80
AstraZeneca · Sites in Taiwan, Argentina, Egypt and 4 more countries
Ages 18+
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
158 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 45 · Phase 4 12
First in 2000; this study’s year is marked. 13 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 139 across the 124 interventional studies, 120 across the 33 observational. Of the 104 that completed or were terminated, 41 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 158 have an industry lead sponsor. The 10 most frequent:
Kaohsiung Medical University Chung-Ho Memorial Hospital is the lead sponsor of 292 studies on the registry; 59 are open to participants now.
Kaohsiung Medical University Chung-Ho Memorial Hospital has 4 studies filed under Pulmonary Disease, Chronic Obstructive — fewer than ten, so there is no comparison to draw.
14 of the studies in Pulmonary Disease, Chronic Obstructive with a site in Taiwan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05878769Phase 3Hoffmann-La RocheA Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | 2027-06-30 |
| NCT06491043Meribank Biotech Co., Ltd.Treatment of Chronic Obstructive Pulmonary Disease by Infusion of Allogenic Mesenchymal Stem Cells | 2026-12-30 |
| NCT06851195Kaohsiung Medical University Chung-Ho Memorial HospitalEffect of Neuromuscular Electrical Stimulation of Lower Limbs on Improving Exercise Self-Efficacy, Dyspnea During Activity and Fatigue in Patients With Chronic Obstructive Pulmonary Disease | 2026-12-31 |
| NCT07305649Taipei Veterans General Hospital, TaiwanThe Effectiveness of an Innovative Inhalation Training Device in Improving Medication Accuracy, Dyspnea, and Quality of Life in Elderly Patients With Chronic Obstructive Pulmonary Disease | 2026-12-31 |
| NCT07474220Fu Jen Catholic UniversityExpression of SLC25A48 in Chronic Obstructive Pulmonary Disease | 2026-12-31 |
Add all 14 to your calendar (.ics) → With an account.
Among the 158 studies in Pulmonary Disease, Chronic Obstructive with a site in Taiwan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Patients diagnosed with COPD who meet the inclusion and exclusion criteria, either inpatients or outpatients, will be informed about the study'sstudy's purpose and procedures by the principal investigator. After understanding their rights, they will provide informed consent.
The process of the experiment The study adopts a quasi-experimental design with convenience sampling. Data collection will be done through structured questionnaires. Patients who meet the inclusion criteria will be referred by physicians, and before enrollment, a verbal introduction will be given explaining the study's purpose, the questionnaire, and the intervention procedure and duration. The experimental group will participate in both pulmonary rehabilitation exercises and an additional intervention of lower limb neuromuscular electrical stimulation, 30 minutes per session, three times per week, for eight weeks. The control group will only participate in pulmonary rehabilitation exercises. Neuromuscular electrical stimulation should continue for 4 to 8 weeks. Questionnaires will be administered before the intervention and at the 2nd, 4th, 6th, and 8th weeks post-intervention, including basic information, Modified Medical Research Council Dyspnea Scale, Manchester COPD Fatigue Scale, and Self-Efficacy for Exercise Scale. Data collection will take approximately 25 minutes, and questionnaires will be personally retrieved by the researcher.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
lower limb neuromuscular electrical stimulation
The control group only participated in the lung rehabilitation exercise program (after which the control group received electrical stimulation for two months)
Behavioral: pulmonary rehabilitation exercises
The study adopts a quasi-experimental design with convenience sampling. Data collection will be done through structured questionnaires. Patients who meet the inclusion criteria will be referred by physicians, and before enrollment, a verbal introduction will be given explaining the study's purpose, the questionnaire, and the intervention procedure and duration. The experimental group will participate in both pulmonary rehabilitation exercises and an additional intervention of lower limb neuromuscular electrical stimulation, 30 minutes per session, three times per week, for eight weeks. The control group will only participate in pulmonary rehabilitation exercises. Based on Hill et al. (2018), neuromuscular electrical stimulation should continue for 4 to 8 weeks. Questionnaires will be administered before the intervention and at the 2nd, 4th, 6th, and 8th weeks post-intervention, including basic information, Modified Medical Research Council Dyspnea Scale, Manchester COPD Fatigue Scale,
The control group only participated in the lung rehabilitation exercise program (after which the control group received electrical stimulation for two months)
Change exercise self-efficacy
This scale is used to assess an individual's confidence in performing exercise behaviors when faced with various situations that are not conducive to exercise. The Chinese version of the Sports Self-efficacy Scale consists of 10 questions, scored from 0 to 10, to understand the degree of confidence in engaging in sports. "0" represents little confidence, and "10" represents great confidence. The higher the score, the more confident one is in performing sports in the face of various situations and obstacles.
Time frame: 8 weeks
change dyspnea during activity
Modified Medical Research Council(mMRC)
Time frame: 8 weeks
change fatigue
The Manchester fatigue scale (MFS) is divided into three aspects, including fatigue conditions such as physiological level (11 questions), cognitive feelings (9 questions) and psychosocial function (7 questions). There are 27 questions in total, with a five-point scoring method. The scoring method is 1 point for "never", 2 points for "rarely", 3 points for "sometimes", 4 points for "often", and 5 points for "always". The higher the score, the higher the degree of fatigue.
Time frame: 8 weeks
Short Physical Performance Battery
The project leader will collect data on the Short Physical Performance Battery (SPPB) before the intervention and eight weeks after the intervention. If there is no pre-test data of the Short Physical Performance Battery (SPPB), the Short Physical Performance Battery (SPPB) will be administered again two months after the intervention.
Time frame: 8 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Dec 2026, 22 months after the start.
Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 22 months is close to that.
Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →
Kaohsiung Medical University Chung-Ho Memorial Hospital →